Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q46925599 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241020233025.0 | ||
| 008 | 241020nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q46925599 | ||
| 024 | ‡a 0000-0001-6499-310X ‡2 orcid | ||
| 024 | ‡a 7402584819 ‡2 scopus | ||
| 035 | ‡a (OCoLC)Q46925599 | ||
| 100 | 0 | ‡a João F. Pinto ‡9 ast ‡9 es ‡9 sl | |
| 375 | ‡a 1 ‡2 iso5218 | ||
| 400 | 0 | ‡a João F. Pinto ‡c researcher ‡9 en | |
| 400 | 0 | ‡a João F. Pinto ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's Alginate films containing Lactobacillus plantarum as wound dressing for prevention of burn infection | ||
| 670 | ‡a Author's Alginate films containing viable Lactobacillus plantarum: preparation and in vitro evaluation | ||
| 670 | ‡a Author's An Insight Into the Impact of Polymers on the Hydrate Conversion of Olanzapine Form I in Aqueous Suspensions. | ||
| 670 | ‡a Author's Assessment of the extrudability of three different mixtures of saturated polyglycolysed glycerides by determination of the "specific work of extrusion" and by capillary rheometry | ||
| 670 | ‡a Author's Bi-layered self-emulsifying pellets prepared by co-extrusion and spheronization: influence of formulation variables and preliminary study on the in vivo absorption. | ||
| 670 | ‡a Author's Characterization of laminar extrudates manufactured at room temperature in the absence of solvents for the delivery of drugs. | ||
| 670 | ‡a Author's Compressed mini-tablets as a biphasic delivery system. | ||
| 670 | ‡a Author's Construction of a quality index for granules produced by fluidized bed technology and application of the correspondence analysis as a discriminant procedure. | ||
| 670 | ‡a Author's Delivery of drugs from laminar co-extrudates manufactured by a solvent-free process at room temperature | ||
| 670 | ‡a Author's Directly compressed mini matrix tablets containing ibuprofen: preparation and evaluation of sustained release | ||
| 670 | ‡a Author's Effect of polymers in moisture sorption and physical stability of polymorphic olanzapine | ||
| 670 | ‡a Author's Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. | ||
| 670 | ‡a Author's Evaluation of the performance of a new continuous spheronizer | ||
| 670 | ‡a Author's Evaluation of the Potential Use of Laminar Extrudates on Stabilizing Micronized Coumarin Particles by Supercritical Fluids (RESS)-Study of Different RESS Processing Variables and Mode of Operation | ||
| 670 | ‡a Author's Evaluation of the viability of Lactobacillus spp. after the production of different solid dosage forms | ||
| 670 | ‡a Author's Generation of hydrate forms of paroxetine HCl from the amorphous state: an evaluation of thermodynamic and experimental predictive approaches. | ||
| 670 | ‡a Author's Green production of cocrystals using a new solvent-free approach by spray congealing | ||
| 670 | ‡a Author's Identification and characterization of stoichiometric and nonstoichiometric hydrate forms of paroxetine HCl: reversible changes in crystal dimensions as a function of water absorption | ||
| 670 | ‡a Author's Identification of the most relevant factors that affect and reflect the quality of granules by application of canonical and cluster analysis | ||
| 670 | ‡a Author's Investigation on the co-extrudability and spheronization properties of wet masses. | ||
| 670 | ‡a Author's Multilayer laminar co-extrudate as a novel controlled release dosage form | ||
| 670 | ‡a Author's Numerical simulation of in-vitro dispersion and deposition of nanoparticles in dry-powder-inhaler aerosols | ||
| 670 | ‡a Author's Oral bioavailability of silymarin phytocomplex formulated as self-emulsifying pellets | ||
| 670 | ‡a Author's Prediction of the deposition of dry powder aerosols | ||
| 670 | ‡a Author's Preservation of viability and antibacterial activity of Lactobacillus spp. in calcium alginate beads. | ||
| 670 | ‡a Author's Production and characterization of spray-dried theophylline powders prepared from fresh milk for potential use in paediatrics | ||
| 670 | ‡a Author's Production of dosage forms for oral drug delivery by laminar extrusion of wet masses. | ||
| 670 | ‡a Author's Production of nano-solid dispersions using a novel solvent-controlled precipitation process - Benchmarking their in vivo performance with an amorphous micro-sized solid dispersion produced by spray drying | ||
| 670 | ‡a Author's Quantification of theophylline or paracetamol in milk matrices by high-performance liquid chromatography | ||
| 670 | ‡a Author's Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming | ||
| 670 | ‡a Author's Real-time monitoring of cocrystallization processes by solvent evaporation: A near infrared study. | ||
| 670 | ‡a Author's Role of moisture on the physical stability of polymorphic olanzapine | ||
| 670 | ‡a Author's Role of Polymeric Excipients in the Stabilization of Olanzapine when Exposed to Aqueous Environments. | ||
| 670 | ‡a Author's Screening methodologies for the development of spray-dried amorphous solid dispersions. | ||
| 670 | ‡a Author's Site-specific drug delivery systems within the gastro-intestinal tract: from the mouth to the colon. | ||
| 670 | ‡a Author's The influence of drug physical state on the dissolution enhancement of solid dispersions prepared via hot-melt extrusion: a case study using olanzapine. | ||
| 670 | ‡a Author's The influence of the preparation methods on the inclusion of model drugs in a beta-cyclodextrin cavity. | ||
| 670 | ‡a Author's Thermal analysis, X-ray powder diffraction and electron microscopy data related with the production of 1:1 Caffeine:Glutaric Acid cocrystals. | ||
| 670 | ‡a wikidata authority control ‡u https://viaf.org/viaf/98612685 | ||
| 909 | ‡a (scopus) 7402584819 ‡9 1 | ||
| 909 | ‡a (orcid) 000000016499310x ‡9 1 | ||
| 919 | ‡a screeningmethodologiesforthedevelopmentofspraydriedamorphoussoliddispersions ‡A Screening methodologies for the development of spray-dried amorphous solid dispersions. ‡9 1 | ||
| 919 | ‡a roleofmoistureonthephysicalstabilityofpolymorphicolanzapine ‡A Role of moisture on the physical stability of polymorphic olanzapine ‡9 1 | ||
| 919 | ‡a realtimemonitoringofcocrystallizationprocessesbysolventevaporationanearinfraredstudy ‡A Real-time monitoring of cocrystallization processes by solvent evaporation: A near infrared study. ‡9 1 | ||
| 919 | ‡a rationaldesignofnanoparticlestowardstargetingantigenpresentingcellsandimprovedtcellpriming ‡A Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming ‡9 1 | ||
| 919 | ‡a quantificationoftheophyllineorparacetamolinmilkmatricesbyhighperformanceliquidchromatography ‡A Quantification of theophylline or paracetamol in milk matrices by high-performance liquid chromatography ‡9 1 | ||
| 919 | ‡a productionofnanosoliddispersionsusinganovelsolventcontrolledprecipitationprocessbenchmarkingtheirinvivoperformancewithanamorphousmicrosizedsoliddispersionproducedbyspraydrying ‡A Production of nano-solid dispersions using a novel solvent-controlled precipitation process - Benchmarking their in vivo performance with an amorphous micro-sized solid dispersion produced by spray drying ‡9 1 | ||
| 919 | ‡a productionofdosageformsfororaldrugdeliverybylaminarextrusionofwetmasses ‡A Production of dosage forms for oral drug delivery by laminar extrusion of wet masses. ‡9 1 | ||
| 919 | ‡a productionandcharacterizationofspraydriedtheophyllinepowderspreparedfromfreshmilkforpotentialuseinpaediatrics ‡A Production and characterization of spray-dried theophylline powders prepared from fresh milk for potential use in paediatrics ‡9 1 | ||
| 919 | ‡a preservationofviabilityandantibacterialactivityoflactobacillussppincalciumalginatebeads ‡A Preservation of viability and antibacterial activity of Lactobacillus spp. in calcium alginate beads. ‡9 1 | ||
| 919 | ‡a predictionofthedepositionofdrypowderaerosols ‡A Prediction of the deposition of dry powder aerosols ‡9 1 | ||
| 919 | ‡a oralbioavailabilityofsilymarinphytocomplexformulatedasselfemulsifyingpellets ‡A Oral bioavailability of silymarin phytocomplex formulated as self-emulsifying pellets ‡9 1 | ||
| 919 | ‡a numericalsimulationofinvitrodispersionanddepositionofnanoparticlesindrypowderinhaleraerosols ‡A Numerical simulation of in-vitro dispersion and deposition of nanoparticles in dry-powder-inhaler aerosols ‡9 1 | ||
| 919 | ‡a multilayerlaminarcoextrudateasanovelcontrolledreleasedosageform ‡A Multilayer laminar co-extrudate as a novel controlled release dosage form ‡9 1 | ||
| 919 | ‡a investigationonthecoextrudabilityandspheronizationpropertiesofwetmasses ‡A Investigation on the co-extrudability and spheronization properties of wet masses. ‡9 1 | ||
| 919 | ‡a identificationofthemostrelevantfactorsthataffectandreflectthequalityofgranulesbyapplicationofcanonicalandclusteranalysis ‡A Identification of the most relevant factors that affect and reflect the quality of granules by application of canonical and cluster analysis ‡9 1 | ||
| 919 | ‡a identificationandcharacterizationofstoichiometricandnonstoichiometrichydrateformsofparoxetinehclreversiblechangesincrystaldimensionsasafunctionofwaterabsorption ‡A Identification and characterization of stoichiometric and nonstoichiometric hydrate forms of paroxetine HCl: reversible changes in crystal dimensions as a function of water absorption ‡9 1 | ||
| 919 | ‡a greenproductionofcocrystalsusinganewsolventfreeapproachbyspraycongealing ‡A Green production of cocrystals using a new solvent-free approach by spray congealing ‡9 1 | ||
| 919 | ‡a generationofhydrateformsofparoxetinehclfromtheamorphousstateanevaluationofthermodynamicandexperimentalpredictiveapproaches ‡A Generation of hydrate forms of paroxetine HCl from the amorphous state: an evaluation of thermodynamic and experimental predictive approaches. ‡9 1 | ||
| 919 | ‡a evaluationoftheviabilityoflactobacillussppaftertheproductionofdifferentsoliddosageforms ‡A Evaluation of the viability of Lactobacillus spp. after the production of different solid dosage forms ‡9 1 | ||
| 919 | ‡a evaluationofthepotentialuseoflaminarextrudatesonstabilizingmicronizedcoumarinparticlesbysupercriticalfluidsressstudyofdifferentressprocessingvariablesandmodeofoperation ‡A Evaluation of the Potential Use of Laminar Extrudates on Stabilizing Micronized Coumarin Particles by Supercritical Fluids (RESS)-Study of Different RESS Processing Variables and Mode of Operation ‡9 1 | ||
| 919 | ‡a evaluationoftheperformanceofanewcontinuousspheronizer ‡A Evaluation of the performance of a new continuous spheronizer ‡9 1 | ||
| 919 | ‡a evaluationofthefusioninhibitorp3peptideasapotentialmicrobicidetopreventhivtransmissioninwomen ‡A Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. ‡9 1 | ||
| 919 | ‡a effectofpolymersinmoisturesorptionandphysicalstabilityofpolymorphicolanzapine ‡A Effect of polymers in moisture sorption and physical stability of polymorphic olanzapine ‡9 1 | ||
| 919 | ‡a directlycompressedminimatrixtabletscontainingibuprofenpreparationandevaluationofsustainedrelease ‡A Directly compressed mini matrix tablets containing ibuprofen: preparation and evaluation of sustained release ‡9 1 | ||
| 919 | ‡a deliveryofdrugsfromlaminarcoextrudatesmanufacturedbyasolventfreeprocessatroomtemperature ‡A Delivery of drugs from laminar co-extrudates manufactured by a solvent-free process at room temperature ‡9 1 | ||
| 919 | ‡a constructionofaqualityindexforgranulesproducedbyfluidizedbedtechnologyandapplicationofthecorrespondenceanalysisasadiscriminantprocedure ‡A Construction of a quality index for granules produced by fluidized bed technology and application of the correspondence analysis as a discriminant procedure. ‡9 1 | ||
| 919 | ‡a compressedminitabletsasabiphasicdeliverysystem ‡A Compressed mini-tablets as a biphasic delivery system. ‡9 1 | ||
| 919 | ‡a characterizationoflaminarextrudatesmanufacturedatroomtemperatureintheabsenceofsolventsforthedeliveryofdrugs ‡A Characterization of laminar extrudates manufactured at room temperature in the absence of solvents for the delivery of drugs. ‡9 1 | ||
| 919 | ‡a bilayeredselfemulsifyingpelletspreparedbycoextrusionandspheronizationinfluenceofformulationvariablesandpreliminarystudyontheinvivoabsorption ‡A Bi-layered self-emulsifying pellets prepared by co-extrusion and spheronization: influence of formulation variables and preliminary study on the in vivo absorption. ‡9 1 | ||
| 919 | ‡a assessmentoftheextrudabilityof3differentmixturesofsaturatedpolyglycolysedglyceridesbydeterminationofthespecificworkofextrusionandbycapillaryrheometry ‡A Assessment of the extrudability of three different mixtures of saturated polyglycolysed glycerides by determination of the "specific work of extrusion" and by capillary rheometry ‡9 1 | ||
| 919 | ‡a insightintotheimpactofpolymersonthehydrateconversionofolanzapineform1inaqueoussuspensions ‡A An Insight Into the Impact of Polymers on the Hydrate Conversion of Olanzapine Form I in Aqueous Suspensions. ‡9 1 | ||
| 919 | ‡a alginatefilmscontainingviablelactobacillusplantarumpreparationandinvitroevaluation ‡A Alginate films containing viable Lactobacillus plantarum: preparation and in vitro evaluation ‡9 1 | ||
| 919 | ‡a alginatefilmscontaininglactobacillusplantarumaswounddressingforpreventionofburninfection ‡A Alginate films containing Lactobacillus plantarum as wound dressing for prevention of burn infection ‡9 1 | ||
| 919 | ‡a roleofpolymericexcipientsinthestabilizationofolanzapinewhenexposedtoaqueousenvironments ‡A Role of Polymeric Excipients in the Stabilization of Olanzapine when Exposed to Aqueous Environments. ‡9 1 | ||
| 919 | ‡a thermalanalysis10raypowderdiffractionandelectronmicroscopydatarelatedwiththeproductionof11caffeineglutaricacidcocrystals ‡A Thermal analysis, X-ray powder diffraction and electron microscopy data related with the production of 1:1 Caffeine:Glutaric Acid cocrystals. ‡9 1 | ||
| 919 | ‡a influenceofthepreparationmethodsontheinclusionofmodeldrugsinabetacyclodextrincavity ‡A The influence of the preparation methods on the inclusion of model drugs in a beta-cyclodextrin cavity. ‡9 1 | ||
| 919 | ‡a influenceofdrugphysicalstateonthedissolutionenhancementofsoliddispersionspreparedviahotmeltextrusionacasestudyusingolanzapine ‡A The influence of drug physical state on the dissolution enhancement of solid dispersions prepared via hot-melt extrusion: a case study using olanzapine. ‡9 1 | ||
| 919 | ‡a sitespecificdrugdeliverysystemswithinthegastrointestinaltractfromthemouthtothecolon ‡A Site-specific drug delivery systems within the gastro-intestinal tract: from the mouth to the colon. ‡9 1 | ||
| 946 | ‡a b ‡9 1 | ||
| 996 | ‡2 DNB|1068195126 | ||
| 996 | ‡2 ISNI|0000000115912991 | ||
| 996 | ‡2 PTBNP|1203257 | ||
| 996 | ‡2 PTBNP|918354 | ||
| 996 | ‡2 DNB|1061376826 | ||
| 996 | ‡2 PTBNP|1057157 | ||
| 996 | ‡2 ISNI|0000000079953904 | ||
| 996 | ‡2 PTBNP|889198 | ||
| 996 | ‡2 ISNI|0000000116994589 | ||
| 996 | ‡2 J9U|987007426341605171 | ||
| 996 | ‡2 ISNI|0000000080787827 | ||
| 996 | ‡2 PTBNP|1196665 | ||
| 996 | ‡2 BAV|495_100999 | ||
| 996 | ‡2 ISNI|0000000069484200 | ||
| 996 | ‡2 PTBNP|1405344 | ||
| 996 | ‡2 BLBNB|000203428 | ||
| 996 | ‡2 ISNI|0000000068476137 | ||
| 996 | ‡2 CAOONL|ncf11898627 | ||
| 996 | ‡2 PTBNP|1808643 | ||
| 996 | ‡2 PTBNP|195079 | ||
| 996 | ‡2 BNE|XX5200841 | ||
| 996 | ‡2 BLBNB|000422047 | ||
| 996 | ‡2 PTBNP|172415 | ||
| 996 | ‡2 ISNI|0000000069822943 | ||
| 996 | ‡2 PTBNP|1383615 | ||
| 996 | ‡2 ISNI|0000000069623514 | ||
| 996 | ‡2 PTBNP|191354 | ||
| 996 | ‡2 LC|nb2022014744 | ||
| 996 | ‡2 PTBNP|1171435 | ||
| 996 | ‡2 LC|no2005025328 | ||
| 996 | ‡2 CAOONL|ncf10910408 | ||
| 996 | ‡2 J9U|987012500911505171 | ||
| 996 | ‡2 DNB|1055187871 | ||
| 996 | ‡2 BNCHL|10000000000000000166636 | ||
| 996 | ‡2 BIBSYS|90337656 | ||
| 996 | ‡2 DNB|1061517381 | ||
| 996 | ‡2 J9U|987007593268505171 | ||
| 996 | ‡2 J9U|987007272518105171 | ||
| 996 | ‡2 DNB|1057335967 | ||
| 996 | ‡2 DNB|172571146 | ||
| 996 | ‡2 DNB|1285000579 | ||
| 996 | ‡2 ISNI|0000000068512943 | ||
| 996 | ‡2 SUDOC|162010540 | ||
| 996 | ‡2 NSK|000505379 | ||
| 996 | ‡2 BNF|12065135 | ||
| 996 | ‡2 PTBNP|1437364 | ||
| 996 | ‡2 BIBSYS|6069189 | ||
| 996 | ‡2 PTBNP|1549204 | ||
| 996 | ‡2 BNF|15285096 | ||
| 996 | ‡2 PTBNP|1055245 | ||
| 996 | ‡2 ISNI|0000000068988896 | ||
| 996 | ‡2 NTA|393160645 | ||
| 996 | ‡2 PTBNP|1925451 | ||
| 996 | ‡2 ISNI|0000000079972814 | ||
| 996 | ‡2 DNB|170314901 | ||
| 996 | ‡2 NUKAT|n 2015010330 | ||
| 996 | ‡2 LC|nr 94025625 | ||
| 996 | ‡2 PTBNP|1608629 | ||
| 996 | ‡2 SUDOC|02922389X | ||
| 996 | ‡2 ISNI|0000000140767677 | ||
| 996 | ‡2 PTBNP|1345073 | ||
| 996 | ‡2 PTBNP|1484469 | ||
| 996 | ‡2 J9U|987007274923805171 | ||
| 996 | ‡2 PTBNP|1680871 | ||
| 996 | ‡2 DNB|1220927619 | ||
| 996 | ‡2 SUDOC|149505736 | ||
| 996 | ‡2 LC|nr 91008198 | ||
| 996 | ‡2 ISNI|000000006998941X | ||
| 996 | ‡2 DNB|1061474445 | ||
| 996 | ‡2 ISNI|0000000069619806 | ||
| 996 | ‡2 ISNI|0000000070724275 | ||
| 996 | ‡2 ISNI|0000000032967057 | ||
| 996 | ‡2 LC|n 2012017616 | ||
| 996 | ‡2 ISNI|0000000070806780 | ||
| 996 | ‡2 ISNI|0000000023295455 | ||
| 996 | ‡2 JPG|500036255 | ||
| 996 | ‡2 PTBNP|262594 | ||
| 996 | ‡2 NTA|071382291 | ||
| 996 | ‡2 NDL|00744924 | ||
| 996 | ‡2 LC|n 2021004023 | ||
| 996 | ‡2 LC|n 2006218728 | ||
| 996 | ‡2 ISNI|0000000048754435 | ||
| 996 | ‡2 PTBNP|1238887 | ||
| 996 | ‡2 NSK|000339025 | ||
| 996 | ‡2 ISNI|0000000114207721 | ||
| 996 | ‡2 LC|n 79145468 | ||
| 996 | ‡2 PTBNP|51061 | ||
| 996 | ‡2 ISNI|0000000036615622 | ||
| 996 | ‡2 BLBNB|000163025 | ||
| 996 | ‡2 LC|no 91011648 | ||
| 996 | ‡2 PTBNP|1758758 | ||
| 996 | ‡2 LC|n 2001910047 | ||
| 996 | ‡2 ISNI|000000007059794X | ||
| 996 | ‡2 BNF|12285570 | ||
| 996 | ‡2 KRNLK|KAC2020R8460 | ||
| 996 | ‡2 PTBNP|1884575 | ||
| 996 | ‡2 LC|no2016055399 | ||
| 996 | ‡2 ISNI|0000000035940933 | ||
| 996 | ‡2 ISNI|0000000068987092 | ||
| 996 | ‡2 NUKAT|n 2022201650 | ||
| 996 | ‡2 BNF|12089484 | ||
| 996 | ‡2 PTBNP|1424895 | ||
| 996 | ‡2 BLBNB|000398381 | ||
| 996 | ‡2 PTBNP|408368 | ||
| 996 | ‡2 DNB|133625656 | ||
| 996 | ‡2 BLBNB|001474675 | ||
| 996 | ‡2 ISNI|0000000069788693 | ||
| 996 | ‡2 ISNI|0000000078035677 | ||
| 996 | ‡2 BLBNB|001020792 | ||
| 996 | ‡2 BLBNB|001024372 | ||
| 996 | ‡2 BLBNB|001028399 | ||
| 996 | ‡2 PTBNP|1155224 | ||
| 996 | ‡2 ISNI|000000006851085X | ||
| 996 | ‡2 ISNI|0000000122669440 | ||
| 996 | ‡2 ISNI|0000000024739740 | ||
| 996 | ‡2 LC|n 79102607 | ||
| 996 | ‡2 ISNI|0000000069832017 | ||
| 996 | ‡2 LC|n 2019045462 | ||
| 996 | ‡2 PTBNP|270459 | ||
| 996 | ‡2 PTBNP|249432 | ||
| 996 | ‡2 PTBNP|1766456 | ||
| 996 | ‡2 ISNI|000000006890017X | ||
| 996 | ‡2 ISNI|0000000025444944 | ||
| 996 | ‡2 LC|no2022084232 | ||
| 996 | ‡2 PTBNP|1448871 | ||
| 996 | ‡2 PTBNP|1452209 | ||
| 996 | ‡2 PTBNP|1329343 | ||
| 996 | ‡2 PTBNP|1850945 | ||
| 996 | ‡2 LC|n 88636122 | ||
| 996 | ‡2 SUDOC|160676223 | ||
| 996 | ‡2 PTBNP|311524 | ||
| 996 | ‡2 ISNI|0000000428473985 | ||
| 996 | ‡2 PTBNP|1452383 | ||
| 996 | ‡2 PTBNP|1433275 | ||
| 996 | ‡2 DNB|105749139X | ||
| 996 | ‡2 PTBNP|1571325 | ||
| 996 | ‡2 SZ|1124846875 | ||
| 996 | ‡2 NII|DA08140375 | ||
| 996 | ‡2 J9U|987007405355405171 | ||
| 996 | ‡2 PTBNP|1432127 | ||
| 996 | ‡2 ISNI|000000002479749X | ||
| 996 | ‡2 LC|n 93901047 | ||
| 996 | ‡2 RERO|A003696176 | ||
| 996 | ‡2 ISNI|0000000078088066 | ||
| 996 | ‡2 SUDOC|113963378 | ||
| 996 | ‡2 RERO|A003696173 | ||
| 996 | ‡2 RERO|A003696172 | ||
| 996 | ‡2 DNB|1124846875 | ||
| 996 | ‡2 NUKAT|n 2020060314 | ||
| 996 | ‡2 ISNI|0000000069411159 | ||
| 996 | ‡2 PTBNP|928133 | ||
| 996 | ‡2 SUDOC|201835800 | ||
| 996 | ‡2 DNB|1157183190 | ||
| 996 | ‡2 DNB|1053307292 | ||
| 996 | ‡2 PTBNP|1532946 | ||
| 996 | ‡2 PTBNP|1158155 | ||
| 996 | ‡2 ISNI|0000000045478244 | ||
| 996 | ‡2 ISNI|0000000069793783 | ||
| 996 | ‡2 ISNI|0000000069802184 | ||
| 996 | ‡2 BLBNB|001515618 | ||
| 996 | ‡2 PTBNP|1816309 | ||
| 996 | ‡2 LC|no2017059470 | ||
| 996 | ‡2 BNF|14624951 | ||
| 996 | ‡2 NUKAT|n 2013006077 | ||
| 996 | ‡2 BNF|12883105 | ||
| 996 | ‡2 BNF|12370546 | ||
| 996 | ‡2 LC|n 86011104 | ||
| 996 | ‡2 ISNI|0000000069113135 | ||
| 996 | ‡2 NTA|07004256X | ||
| 996 | ‡2 ISNI|0000000067794483 | ||
| 996 | ‡2 SUDOC|144791153 | ||
| 996 | ‡2 LC|no2005068626 | ||
| 996 | ‡2 NTA|26029716X | ||
| 996 | ‡2 ISNI|0000000069896950 | ||
| 996 | ‡2 BLBNB|000323123 | ||
| 996 | ‡2 BLBNB|000271315 | ||
| 996 | ‡2 SUDOC|028914074 | ||
| 996 | ‡2 PTBNP|1000406 | ||
| 996 | ‡2 ISNI|0000000107770655 | ||
| 996 | ‡2 NII|DA06818479 | ||
| 996 | ‡2 LC|n 85332995 | ||
| 996 | ‡2 SUDOC|160124158 | ||
| 996 | ‡2 BLBNB|000206936 | ||
| 996 | ‡2 NTA|151070296 | ||
| 996 | ‡2 PTBNP|159319 | ||
| 996 | ‡2 NTA|297889664 | ||
| 996 | ‡2 LC|n 2011047665 | ||
| 996 | ‡2 PTBNP|1448388 | ||
| 996 | ‡2 ISNI|0000000069896037 | ||
| 996 | ‡2 BLBNB|000368757 | ||
| 996 | ‡2 PTBNP|1607511 | ||
| 996 | ‡2 PTBNP|983166 | ||
| 996 | ‡2 BNC|981058598285006706 | ||
| 996 | ‡2 PTBNP|1030702 | ||
| 996 | ‡2 LC|n 95042620 | ||
| 996 | ‡2 PTBNP|1646053 | ||
| 996 | ‡2 BLBNB|000273913 | ||
| 996 | ‡2 PTBNP|1334985 | ||
| 996 | ‡2 ISNI|0000000069517041 | ||
| 996 | ‡2 NUKAT|n 2006124424 | ||
| 996 | ‡2 PTBNP|119181 | ||
| 996 | ‡2 PTBNP|1718956 | ||
| 996 | ‡2 BLBNB|000587114 | ||
| 996 | ‡2 PTBNP|70078 | ||
| 996 | ‡2 DNB|1043023917 | ||
| 996 | ‡2 NKC|mub2015878919 | ||
| 996 | ‡2 ISNI|0000000066622858 | ||
| 996 | ‡2 SUDOC|073385514 | ||
| 996 | ‡2 PTBNP|1660338 | ||
| 996 | ‡2 ISNI|0000000072828529 | ||
| 996 | ‡2 B2Q|0000446444 | ||
| 996 | ‡2 ISNI|0000000070224916 | ||
| 996 | ‡2 ISNI|0000000070329937 | ||
| 996 | ‡2 ISNI|0000000069803099 | ||
| 996 | ‡2 ISNI|0000000068681595 | ||
| 996 | ‡2 ISNI|0000000068275300 | ||
| 996 | ‡2 SUDOC|072481757 | ||
| 996 | ‡2 ISNI|0000000444677443 | ||
| 996 | ‡2 DNB|1164114832 | ||
| 996 | ‡2 BNF|12037998 | ||
| 996 | ‡2 SUDOC|032731639 | ||
| 996 | ‡2 ISNI|0000000111111257 | ||
| 996 | ‡2 DNB|1220705128 | ||
| 996 | ‡2 LC|n 96101686 | ||
| 996 | ‡2 SUDOC|262572591 | ||
| 996 | ‡2 NUKAT|n 2019214890 | ||
| 996 | ‡2 ISNI|000000003852912X | ||
| 996 | ‡2 DNB|1160310947 | ||
| 996 | ‡2 PTBNP|1405704 | ||
| 996 | ‡2 ISNI|0000000036384246 | ||
| 996 | ‡2 SUDOC|265367476 | ||
| 996 | ‡2 PTBNP|356447 | ||
| 996 | ‡2 DNB|171488229 | ||
| 996 | ‡2 LC|n 85057630 | ||
| 996 | ‡2 PTBNP|91487 | ||
| 996 | ‡2 SUDOC|077789180 | ||
| 996 | ‡2 NUKAT|n 2010165248 | ||
| 996 | ‡2 DNB|1157165397 | ||
| 996 | ‡2 PTBNP|1554000 | ||
| 996 | ‡2 ISNI|0000000070326058 | ||
| 996 | ‡2 SUDOC|095888705 | ||
| 996 | ‡2 ISNI|0000000113254016 | ||
| 996 | ‡2 DNB|1051929350 | ||
| 996 | ‡2 ISNI|0000000367368726 | ||
| 996 | ‡2 NTA|408455489 | ||
| 996 | ‡2 PTBNP|1711917 | ||
| 996 | ‡2 BLBNB|000358910 | ||
| 996 | ‡2 ISNI|0000000070701954 | ||
| 996 | ‡2 ISNI|0000000031946836 | ||
| 996 | ‡2 LC|n 78087675 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 | ||
| 998 | ‡a Pinto, ‡b João ‡2 PTBNP|1052056 ‡3 title: (0.86, 'evaluationoftheviabilityoflactobacillussppindifferentdosageforms', 'evaluationoftheviabilityoflactobacillussppaftertheproductionofdifferentsoliddosageforms') | ||
| 998 | ‡a Pinto, João ‡2 ISNI|0000000069788693 ‡3 viafid | ||
| 998 | ‡a Pinto, ‡b João Fernandes ‡2 PTBNP|1316934 ‡3 title: (0.65, 'developmentofnewscreeningmethodologiesandpreparationmethodswithapplicationinamorphoussoliddispersionsandpharmaceuticalcocrystals', 'screeningmethodologiesforthedevelopmentofspraydriedamorphoussoliddispersions') ‡3 viafid |
